YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Browse Top Headlines

Search Text
Start Date
End Date

14M Genomics Spins out of Sanger

TODAY | Business Weekly | A new genomics powerhouse, 14M Genomics, spun out of the world famous Wellcome Trust Sanger Institute, has been launched in the Cambridge UK technology cluster with a £12.5 million financing.

Big Pharma Moves to Boston

TODAY | Boston Globe | Big pharma is expanding its reach in the Boston area, picking up small to mid-sized biotechs for billions of dollars. Last week Merck announced plans to buy Cubist Pharmaceuticals for $9.5 billion.

Quanterix Offers Lab Access to Simoa Protein Analyzer

| Bio-IT World News Brief | Quanterix today announced the opening of a Simoa Accelerator in Lexington, Mass., where scientists and can rent access to the company's high-throughput Simoa instruments for protein analysis.

Retraction Watch to Build Comprehensive Database of Retractions

| Bio-IT World News Brief | Retraction Watch, a popular blog founded in 2010 to investigate retractions in the scientific literature, has received a two-year grant from the MacArthur Foundation to compile a database of all retractions, corrections, and expressions of concern in every field of science.

Smithsonian jumps into biodiversity genomics with new institute

| Science/AAAS News | The Smithsonian Institution plans to launch a virtual biodiversity genomics institute to catalog DNA from the earth's flora and fauna. To coordinate biodiversity genomics, the Smithsonian hopes to raise $100 million over the next 10 years.

Agenda: Informatics Channel at MMTC

| Bio-IT World | The Molecular Medicine Tri-Conference in San Francisco has a rich agenda with four content channels in addition to short courses and symposia. This year we are particularly interested in the Informatics Channel. Here’s the working draft of our agenda.

Annai Hosts International Cancer Genome Consortium Data

| Bio-IT World | Data generated by the International Cancer Genome Consortium, including whole genomes, exomes, and RNA-seq, will now be made available to researchers through Annai Systems' ShareSeq platform.

Intriguing Results for Nanopore Sequencing from Defunct Roche-IBM Partnership

| Bio-IT World | Researchers from Arizona State University and IBM’s TJ Watson Research Center present the development of a solid state tunneling device sensitive to nucleotides. The next steps may reveal the direction in which nanopore sequencing is heading.

Study finds support for newborn genetic testing among parents

| Boston Herald | Most parents would like to have their newborns genetically tested for medical conditions and disorders, according to a new study published this wee

BaseHealth, Labco Sign European Partnership

| Bio-IT World | BaseHealth of Redwood City, Calif., has announced a partnership with the European diagnostics network Labco to deploy BaseHealth’s Genophen platform to thousands of physicians across Europe

Druggability: An Underappreciated Issue in Translating the Human Genome Into Therapeutics

| Omics! Omics! Blog | Keith Robison: "It's sobering to think how few of the targets of current therapeutics could be found from genomics data."

Controversy Over CRISPR Patents

| MIT Technology Review | As Editas Medicine claims exclusive licenses to use key intellectual property around the CRISPR-Cas9 gene editing system, many of the innovators of this technology are disputing patent priority, or even the right to patent foundational CRISPR engineering techniques.

Pharma Multi-Millionaire Gives 100 Million To University of North Carolina

| Forbes | Former pharmaceutical executive Fred Eshelman has pledged $100 million to spur innovation at the UNC's pharmacy school.

MIT and Massachusetts General Hospital Team Up on New Microbiome-Based Therapies

| Bio-IT World | Eric Alm, co-director of the new Center for Microbiome Informatics and Therapeutics at MIT and MGH, talks microbial therapies, new regulatory models, and the public appeal of our microbes.

IP Deals Shed Light on Editas Medicine’s Strategy for CRISPR Gene Therapies

| Bio-IT World | Editas Medicine, a Cambridge company tackling therapies based on CRISPR gene editing, announced three intellectual property licensing deals with major research institutions this week, gaining exclusive access to key CRISPR-related technologies.

What Pharma Recruiters Are Looking for in Asia

| in-PharmaTechnologist | Singaporean companies are looking for scientists, while China and India need execs - but don't count on moving to Japan, says jobs expert Doris Chin.

Nature Makes Full Text Papers Available Via ReadCube

| Nature News | Nature Publishing Group announced this morning that all of its research papers will now be free to read via ReadCube, a proprietary screen-view format that can be annotated but not copied, printed, or downloaded

Hackers Target Pharma, Health Care Companies

| New York Times | A hacking ring nicknamed Fin4 has been targeting pharma and healthcare companies by hacking into email accounts.

Holiday Reading for a CRISPR Autumn Day

| Bio-IT World | This year has seen the rapid rise of CRISPR gene editing, for which the biotech industry has every reason to be thankful. Intellia Therapeutics, based in Cambridge, Mass., is the third CRISPR company to spring up in the last twelve months, joining Editas Medicine also in Cambridge, and CRISPR Therapeutics, which operates out of Basel and London. Here is a selection of our coverage on this remarkably adaptable gene engineering system.

Misidentified Cell Line List from NCBI

| NCBI News | NCBI's BioSample database now includes a curated list of over 400 known misidentified and contaminated cell lines.
 1        


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.